QurAlis Demonstrates Target Engagement of QRL-101 in ALS Patients, Advancing Precision Medicine for Neurological Disorders
Key Insights
QurAlis (search) reported first-time evidence of target engagement with selective Kv7.2/7.3 (search) ion channel opener QRL-101 in ALS (search) patients, showing reduced motor-neuron hyperexcitability compared to placebo.
The Phase 1 proof-of-mechanism trial demonstrated consistent safety and tolerability profiles, with no serious adverse events or discontinuations reported in the 12-participant study.
QRL-101 targets hyperexcitability caused by KCNQ2 (search) gene mis-splicing linked to TDP-43 dysfunction, with the company planning Phase 2 trials for both ALS (search) and developmental epileptic encephalopathies.
QurAlis Corporation has achieved a significant milestone in neurological drug development, reporting the first evidence of target engagement with its selective Kv7.2/7.3 (search) ion channel opener QRL-101 in patients with amyotrophic lateral sclerosis (search) (ALS (search)). The Phase 1 proof-of-mechanism clinical trial demonstrated reduced motor-neuron hyperexcitability compared to placebo, marking a crucial step toward precision medicine for neurodegenerative diseases.
Breakthrough in ALS Target Engagement
The QRL-101-04 study represents the first demonstration of target engagement with a selective Kv7.2/7.3 (search) ion channel opener in ALS (search) patients. Results showed reduced motor-neuron hyperexcitability compared to placebo, with more robust responses observed in patients with higher exposure to QRL-101. The findings were consistent across multiple measures including strength-duration time constant (SDTC), rheobase, and eight of nine additional measures evaluated as part of the motor nerve excitability threshold tracking (mNETT) assessment.
"This is the first time we are seeing target engagement of QRL-101 in ALS (search) patients with a biomarker which predicts survival in ALS," said Kasper Roet, Ph.D., CEO and co-founder of QurAlis (search). "This is extremely encouraging as new research published in Nature Neuroscience provides additional evidence that loss of TDP-43 function drives mis-splicing of the KCNQ2 (search) potassium channel, producing a dysfunctional isoform that disrupts neuronal excitability in ALS and frontotemporal dementia (search)."
Targeting Hyperexcitability Mechanisms
QRL-101 addresses hyperexcitability-induced disease progression in ALS (search), which occurs in both sporadic and genetic forms of the disease. The majority of cases are caused by mis-splicing of the KCNQ2 (search) gene in the pre-mRNA. Kv7.2/7.3 (search) is a voltage-gated potassium channel crucial for regulating neuronal excitability and membrane potential, representing a clinically validated target for managing hyperexcitable states.
Preclinical studies have demonstrated that QRL-101 is more potent and exhibits the potential for fewer clinical adverse events than ezogabine, a less selective, first-generation Kv7.2/7.3 (search) channel opener. This positions QRL-101 as a potentially best-in-class treatment option.
Clinical Trial Design and Safety Profile
The QRL-101-04 trial was a Phase 1 proof-of-mechanism single-dose, placebo-controlled study that enrolled 12 participants with ALS (search). The study evaluated the impact of QRL-101 on motor nerve excitability threshold tracking across three different dose levels, with participants randomized 3:1 between QRL-101 and placebo.
The safety and tolerability profile of QRL-101 was consistent with previously reported study results. Notably, there were no serious adverse events or discontinuations due to adverse events reported in the study. The pharmacokinetic profile also aligned with previous findings.
Dual Development Strategy
QurAlis (search) is advancing QRL-101 for both ALS (search) and developmental and epileptic encephalopathies (search) (DEE (search)). The company is currently planning a Phase 2 clinical trial to explore the effects of QRL-101 in DEE, leveraging the established clinical validation of Kv7 as a target for regulating hyperexcitable states in epilepsy (search).
Supporting evidence from healthy volunteer studies has also been promising. The QRL-101-05 study, a randomized, double-blind, placebo-controlled, three-way crossover clinical trial in healthy volunteers, showed evidence of brain penetration, target engagement, and potential anti-seizure effects demonstrated through biomarkers for transcranial magnetic stimulation electromyography (TMS-EMG) and electroencephalography (EEG).
Future Clinical Development
QurAlis (search) intends to advance QRL-101 into Phase 2 proof-of-concept clinical trials as a potentially best-in-class treatment for both DEE (search) and ALS (search). The primary endpoint of the current study was exploration of the pharmacokinetic and pharmacodynamic relationship of QRL-101 and was not powered to demonstrate statistically significant differences between QRL-101 and placebo arms.
The company's approach represents a precision medicine strategy targeting specific genetic and molecular mechanisms underlying neurological hyperexcitability, potentially offering new therapeutic options for patients with limited treatment alternatives in both ALS (search) and epilepsy (search) disorders.